Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer may soon play pharmaceutical musical chairs by relocating some of its overseas drug production back to the U.S., responding to the tariff tango initiated by President Trump. Pfizer CEO Albert ...

Read on to learn why. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, ...

Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...